Scott Turicchi - j2 Global, Inc.
Management
Right. It wasn't in our DNA, but nevertheless we said look, we want good value for that asset. We believe in this asset, we believe in this space, but that was our bottom line. So we were not prepared to give the asset away. So, we knew in certain scenarios we'd run it. Then, yes, it was competitive. And yes, there were multiple bids. But some wanted to give us all cash. That's nice. We can always use cash and redeploy it, but that would give us, you know, basically limit – well, in one case, I think there was a little bit of upside in a much larger company. In another case, it was pure cash. So we had virtually no upside in the asset. What was to us very fascinating about Welltok is that they have a suite of health IT services and Tea Leaves actually fit very nicely into their portfolio. So it makes them stronger. They have a great leader in Jeff Margolis, who has already taken a company public and done very well with it. So when they emerged as one of the bidders, then we started to think real hard about, all right, can we end up with sort of a couple of benefits, really three. Put the asset in a better set of hands who's likely to, you know, get the full value out of it. In this case, move into to a diversified portfolio. So our upside isn't limited to just what Tea Leaves does, but it's against the whole portfolio of Welltok. And also have a great senior management team who this is what they do because, this is their DNA. So from a structural standpoint, Welltok met all those criteria. Now, in terms of the price, it's about $90 million. And the reason it's about, is because we got some amount in cash. I'm not allowed to go into the exact terms, but a minority of that $90 million is in cash. We've already collected it, and the remainder is in a couple of different tranches of securities that we receive, which can be converted into equity. And so that's where our upside comes in terms of the future. We looked at the deal. We thought that certainly the total purchase price was fair and good. And we like the fact that we have a fairly meaningful back-end upside in what we think is a very powerful, exciting company in the health IT space. So we'll keep those securities, those are j2 to be clear. Those are j2 wholly-owned securities. So they're ours and at various points over the next several years based upon what Welltok does, I think there'll be various opportunities for monetization of some or all of those securities.